Market Place
Sourcing Support
Zai Lab Study In Cell Offers Insights On HRD-Positive Ovarian Cancer Treatment
15 Jul 2024 //
BUSINESSWIRE
FDA Approves FoundationOne Liquid CDx As Companion Diagnostic For AKEEGA
01 Jul 2024 //
BUSINESSWIRE
Zai Lab to Present Final OS Data from Phase 3 NORA Study of ZEJULA
06 Mar 2024 //
BUSINESSWIRE
In royalty dispute, UK appeals court sides with GSK over AZ
14 Feb 2024 //
FIERCE PHARMA
Niraparib Tosylate-A Promising Treatment for Ovarian Cancer
18 Jan 2024 //
PRESS RELEASE
GSK`s cancer drug combination meets primary goal in late-stage trial
19 Dec 2023 //
PRESS RELEASE
AKEEGA™ (niraparib and abiraterone acetate) Now Available from Onco360
03 Oct 2023 //
BUSINESSWIRE
Niraparib Maintenance Extends PFS in Newly Diagnosed Ovarian Cancer
27 Aug 2023 //
ONCLIVE
FDA approves J&J`s PARP combo drug Akeega for prostate cancer
12 Aug 2023 //
FDA
Janssen gets priority review for prostate cancer; ImmunoGen reports Q1 sales
28 Apr 2023 //
ENDPTS
Eligibility challenges` derail GSK`s Zejula breast cancer trial
27 Apr 2023 //
FIERCE PHARMA
UK court orders GSK to pay AstraZeneca royalties on total sales of Zejula
06 Apr 2023 //
REUTERS
GSK pulls another cancer indication for Zejula at FDA`s request
15 Nov 2022 //
ENDPTS
GSK’s Zejula offers lasting PFS benefit in Phase III ovarian cancer trial
12 Sep 2022 //
CLINICALTRIALSARENA
AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million
12 Sep 2022 //
GLOBENEWSWIRE
Zejula shows sustained progression-free survival benefit in the PRIMA study
09 Sep 2022 //
PRESS RELEASE
Singapore approves GSK`s new cancer therapy for ovarian cancer
04 Jul 2022 //
BIOSPECTRUMASIA
Zai Lab to Present New PRIME Subgroup Analysis for Niraparib
31 May 2022 //
PRESS RELEASE
Janssen Submits MAA for Niraparib & Abiraterone Acetate Dual Action Tablet
28 Apr 2022 //
BUSINESSWIRE
NICE recommends GSK’s ZEJULA (niraparib) for ovarian cancer patients
24 Feb 2022 //
PHARMAFILE
Tempus & GSK Collborate to Begin Open Enrollment for Study of Niraparib
13 Jan 2022 //
BUSINESSWIRE
Zai Lab Announces Inclusion of ZEJULA (Niraparib) in China’s NNRDL
03 Dec 2021 //
GLOBENEWSWIRE
Ivy Brain Tumor Center Collaborates with GSK on New Phase 0
02 Nov 2021 //
PRESS RELEASE
Merck’s Keytruda, GSK’s Zejula cancer plans hampered by Ph II discontinuations
01 Oct 2021 //
CLINICALTRIALSARENA
PARP inhibitors get insurance benefits for 1st-line in ovarian cancer
28 Sep 2021 //
KOREABIOMED
GSK to present new data in oncology pipeline and portfolio at ESMO Congress 2021
11 Sep 2021 //
PHARMABIZ
AZ takes PARP battle against GSK to court
08 Jun 2021 //
FIERCEPHARMA
AZ takes PARP battle against GSK to court
07 Jun 2021 //
FIERCEPHARMA
GSK to highlight scientific research in ovarian & endometrial cancer at SGO 2021
19 Mar 2021 //
PRESS RELEASE
Zai Lab Announces Inclusion of ZEJULA® China’s National Reimbursement Drug List
30 Dec 2020 //
GLOBENEWSWIRE
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) Drug List
29 Dec 2020 //
GLOBENEWSWIRE
EC approves Zejula (niraparib) as a monotherapy for advanced ovarian cancer
02 Nov 2020 //
EUROPEANPHARMACEUTICALREVIEW
European Commission approves Zejula (niraparib) as first-line monotherapy
30 Oct 2020 //
GSK
EU approves Zejula as a first-line monotherapy treatment ovarian cancer
30 Oct 2020 //
PHARMAFILE
With FDA decision looming, GSK sweetens the PD-1 pot for partner AnaptysBio
26 Oct 2020 //
ENDPTS
ZEJULA is approved in Canada for first-line maintenance treatment of women
05 Oct 2020 //
NEWSWISE
Phase 3 NORA Data Of Zejula® (Niraparib) Demonstrate Significant PFS Benefit
20 Sep 2020 //
GLOBENEWSWIRE
EMA Recommends Approval Of GSK’s Zejula As 1st Line For Advanced Ovarian Cancer
20 Sep 2020 //
PHARMABIZ
Byondis Initiates Ph I Study of ADC [Vic-]Trastuzumab Duocarmazine + Niraparib
24 Aug 2020 //
PRESS RELEASE
GlaxoSmithKline pens $120M upfront cancer pact with Ideaya
16 Jun 2020 //
FIERCEBIOTECH
Zai Lab Announces Positive Topline Results from the NORA Ph3 Study of ZEJULA®
28 May 2020 //
GLOBENEWSWIRE
GSK highlights scientific innovation & advances its growing oncology portfolio
20 May 2020 //
PRESS RELEASE
ASCO: Lynparza levels up in ovarian cancer with survival win
13 May 2020 //
FIERCE PHARMA
Lynparza gets broader US ovarian cancer approval
12 May 2020 //
CISION
AZ, Merck`s Lynparza will face GSK in wider ovarian cancer pool
08 May 2020 //
FIERCE PHARMA
FDA gives broader approval to GSK`s Zejula for ovarian cancer
30 Apr 2020 //
FDA
FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor
29 Apr 2020 //
PR NEWSWIRE
GSK`s Zejula jumps ahead of Lynparza with key ovarian cancer nod
29 Apr 2020 //
FIERCE PHARMA
Zai Lab Announces Acceptance of sNDA Submission of ZEJULA® (Niraparib)
16 Mar 2020 //
GLOBENEWSWIRE
U.S. FDA accepts GSK`s sNDA application for Zejula (niraparib)
24 Feb 2020 //
PR NEWSWIRE
Drugmakers rebranding around oncology, rare diseases could provide 2020 preview
20 Dec 2019 //
FIERCE PHARMA
GSK`s Zejula Widens the PARP Scope with New FDA Approval
24 Oct 2019 //
BIOSPACE
GSK nabs expanded Zejula ovarian cancer nod
24 Oct 2019 //
FIERCE PHARMA
GSK Announces USFDA of Additional Indication for Zejula (niraparib)
23 Oct 2019 //
BUSINESSWIRE
US FDA grants breakthrough therapy status to Janssen`s niraparib
05 Oct 2019 //
PHARMABIZ
GSK, AZ-Merck PARP data heap pressure on Clovis: analysts
02 Oct 2019 //
FIERCE PHARMA
Zejula successful in advanced ovarian cancer
02 Oct 2019 //
PHARMATIMES
GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category
01 Oct 2019 //
PMLIVE
AstraZeneca rounds out ESMO for expanded biomarker in prostate cancer
30 Sep 2019 //
ENDPTS
